The research team followed the PRISMA guidelines for systematic reviews, searching MEDLINE via PubMed, Web of Science, and Scopus through June 2026 under a protocol registered with PROSPERO. From an initial pool of 325 potentially relevant articles, the investigators ultimately included twelve studies that met strict eligibility criteria: original research on primary breast cancer that assessed heterogeneity through genomic, transcriptomic, radiomic, or immunologic methods and connected those measurements to chemotherapy response or clinical outcomes. The included cohorts spanned triple-negative breast cancer, HER2-positive disease, hormone receptor-positive tumors, and mixed populations, with sample sizes ranging from just six patients to nearly 1,600.

What makes this review particularly compelling is the sheer diversity of technologies the included studies deployed to peer inside tumors. Some used single-cell DNA and RNA sequencing to track clonal dynamics during treatment. Others relied on MRI-based radiomics, extracting quantitative features from medical images that reflect differences in tumor architecture, vascularization, and perfusion. Still others profiled long non-coding RNAs, mapped spatial immune infiltration, or combined imaging with genomic classifiers. Despite these methodological differences, a consistent pattern emerged: tumors with high or increasing heterogeneity, whether measured at the molecular level or through imaging, tended to show reduced sensitivity to chemotherapy.

The biological mechanisms underlying this resistance appear to be several and distinct. The most striking is adaptive clonal selection, the idea that chemotherapy does not create resistant cells so much as reveal them. In a landmark single-cell sequencing study included in the review, Kim and colleagues followed triple-negative breast tumors through treatment and found that certain clones pre-existed before therapy and survived the drug assault, effectively pruning sensitive cells while allowing resistant ones to dominate. Notably, a minority of pre-treatment cells appeared primed for survival, already expressing subsets of resistance-related genes before any drug exposure. Chemotherapy failure, in other words, may often be driven by the expansion of pre-existing resistant subclones rather than the acquisition of new mutations during treatment.

A second mechanism involves transcriptional plasticity, the capacity of cancer cells to rewire their gene expression programs into drug-tolerant states. Lusby and colleagues mapped the regulatory circuitry underlying chemoresistance in triple-negative disease, identifying super-enhancer-driven transcription factor networks that maintain a pool of resistant cells despite therapy, and deriving a twenty-gene signature predictive of response. Complementing this work, Shaath and colleagues profiled the long non-coding RNA landscape at single-cell resolution and implicated MALAT1, a well-known regulatory RNA, as a mechanistic driver of resistance to neoadjuvant chemotherapy. Functional CRISPR experiments reinforced the link, showing that MALAT1 influences drug sensitivity and regulatory networks, positioning non-coding RNA regulation as both a potential biomarker and a therapeutic avenue.

The tumor microenvironment adds yet another layer of complexity. Immune exclusion, in which regions of heterogeneous tumors lack effective infiltration by cytotoxic T lymphocytes, emerged as a clinically relevant dimension of heterogeneity. Gandhi and colleagues tested a cytokine-kinase mediated immune-priming regimen added to standard neoadjuvant chemotherapy in triple-negative breast cancer and observed encouraging safety, immune remodeling, enhanced CD8-positive T-cell infiltration, and a pathologic complete response rate of 55 percent in a small phase I setting. Meanwhile, other work suggests that growth factors such as HGF and NRG1β can actively preserve diverse basal, luminal, and mesenchymal phenotypes during treatment, sustaining phenotypic diversity rather than merely selecting for resistant clones. Heterogeneity, it seems, is not solely a property of tumor cells but is shaped by ongoing interactions with the surrounding microenvironment.

In HER2-positive disease, the review highlights genomic heterogeneity as a predictor of targeted therapy failure. Two independent studies found that tumors with heterogeneous HER2 amplification patterns, particularly those harboring low-level amplification alongside HER2-amplified subclones, were significantly less likely to achieve pathologic complete response after anti-HER2 neoadjuvant therapy. The coexistence of HER2-amplified and HER2-low cell populations may create a reservoir of intrinsically resistant cells before treatment even begins. Encouragingly, one of these studies showed that HER2 heterogeneity can be assessed using routine pathology data, suggesting that a predictive biomarker could be implemented without exotic new infrastructure.

Perhaps the most clinically provocative strand of evidence concerns imaging. Several included studies demonstrated that MRI-derived measures of heterogeneity can predict treatment response and recurrence risk non-invasively. Huang and colleagues developed an MRI-based heterogeneity nomogram that independently predicted both pathologic complete response and relapse-free survival in a multicenter design with external validation. Shi and colleagues combined ecological diversity concepts with radiomic analysis across multicenter cohorts and showed improved prediction of response. Chitalia and colleagues went further, demonstrating that early spatial-phenotypic shifts visible on MRI could predict recurrence and add predictive power beyond established genomic classifiers such as PAM50. Integrated radiomic-genomic models outperformed either modality alone, and rising heterogeneity during therapy, so-called delta-ITH, offered a promising early, non-invasive indicator of poor outcomes.

The review’s authors are careful to acknowledge significant limitations. The twelve included studies differed substantially in design, patient populations, heterogeneity assessment methods, and outcome definitions, which precluded formal meta-analysis. Most were retrospective, single-center, and based on relatively small cohorts, raising the risk of selection bias. Triple-negative and HER2-positive tumors were overrepresented while estrogen receptor-positive luminal disease was underrepresented, and there is no standardized way to measure heterogeneity across sequencing, radiomics, and immune profiling platforms. Quality assessment using the Newcastle-Ottawa Scale nonetheless rated eight of the twelve studies as high quality, and the consistency of findings across such disparate methods lends credibility to the central conclusion.

The implications for clinical practice are potentially profound but remain aspirational. If heterogeneity can be reliably measured before and during treatment, oncologists could one day stratify patients more accurately, identify those unlikely to benefit from a given regimen, and adapt therapy based on longitudinal heterogeneity signals captured through routine imaging. Such ITH-guided adaptive treatment remains a research question rather than current practice, and the authors emphasize that prospective, multicenter validation with standardized measurement approaches is essential before routine implementation. Still, the message of this synthesis is clear: the average tumor sampled by a single biopsy may be a misleading caricature of the diverse cellular ecosystem within it, and learning to read that diversity, through sequencing, spatial profiling, and the MRI scanner, could be key to finally overcoming chemotherapy resistance in breast cancer.

Subject of Research: Intratumor heterogeneity and chemotherapy resistance in primary breast cancer

Article Title: The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review

Article References: The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review. (n.d.). https://doi.org/10.1007/s12032-026-03426-z

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03426-z

Keywords: intratumor heterogeneity, breast cancer, chemotherapy resistance, triple-negative breast cancer, HER2-positive, radiomics, MRI, single-cell sequencing, neoadjuvant chemotherapy, tumor microenvironment, MALAT1, systematic review

The platform, called lncRNA Seeker Hub, was developed by Pok-Son Kim of Kookmin University, Klaus Heese of Hanyang University’s Graduate School of Biomedical Science and Engineering, and Arne Kutzner of Hanyang University’s Department of Information Systems. Writing in the open-access journal BMC Bioinformatics, the team describes a system that aggregates RNA sequencing evidence across entire cohorts of samples and then lets researchers manually reconstruct transcript structures that automated assemblers cannot reliably recover. The work was supported by a grant from the National Research Foundation of Korea, funded by the Ministry of Science and ICT, and the software’s case studies focus on two of the most famous non-coding RNA loci in human biology: MALAT1 and PCA3.

The core problem the team attacks is statistical and computational at once. When a gene is expressed weakly, any single RNA-seq sample may show only sparse local coverage along the genome, and the reads that do map across splice junctions, the points where RNA segments are stitched together after introns are removed, may be too few to convince an assembler that a genuine transcript exists there. Individual samples also differ from one another in unpredictable ways, so the splicing pattern supported by one patient’s tissue may barely register in another’s. Yet when many samples are pooled, these faint, distributed signals can become reproducible and interpretable. Automated assembly tools, which typically operate sample by sample or merge results only crudely, are poorly suited to exploit that cohort-level pattern. Genome browsers that researchers routinely rely on, including IGV, JBrowse, and the UCSC Genome Browser, offer superb visualization but, according to the authors, lack integrated support for cohort-level aggregation and the kind of hands-on transcript reconstruction their workflow demands.

lncRNA Seeker Hub fills that gap with an architecture that reflects modern software engineering as much as genomics. At its heart sits a high-performance backend written in Rust, a systems programming language prized for speed and memory safety. The backend performs targeted aggregation of BAM files, the standard binary format in which aligned sequencing reads are stored, pulling only the genomic regions of interest rather than loading entire chromosomes. To keep interactive exploration responsive, the system employs binary caching, so that previously computed aggregations can be served instantly on repeat queries. On top of this engine runs an interactive visualization interface built with Bokeh, a Python-based plotting library designed for browser-delivered, data-dense graphics. The combination means a researcher can zoom into a specific gene locus across dozens or hundreds of samples and see aggregated evidence render quickly enough to support genuine, exploratory analysis rather than batch-and-wait processing.

What makes the platform distinctive is not merely speed but the way it synchronizes different layers of evidence. In a single view, a researcher can examine read coverage along the genome, the splice junctions supported by split reads, and the individual reads themselves, all aligned and all drawn from the aggregated cohort rather than from one sample at a time. This synchronized exploration is precisely what weak-lncRNA discovery requires. A candidate exon may show barely detectable coverage in any single individual, yet appear consistently, sample after sample, once the cohort is pooled. A splice junction may lack the read support an assembler demands in isolation, but reveal itself as a recurring pattern when evidence is aggregated. The software then supports manual transcript reconstruction: researchers can build, inspect, and refine candidate transcript structures directly from that aggregated evidence, effectively acting as expert curators of their own data.

The published case studies illustrate the approach at the MALAT1 and PCA3 loci. MALAT1, or metastasis-associated lung adenocarcinoma transcript 1, is one of the most abundant and intensively studied lncRNAs in mammals, involved in regulating gene expression in the cell nucleus and strongly implicated in cancer metastasis. PCA3 is a prostate-specific non-coding RNA used as a biomarker in prostate cancer diagnostics, notable because it is expressed at very low levels compared with most coding genes. At both loci, the authors report that lncRNA Seeker Hub enabled the detection of candidate cohort-supported transcriptional structures and splice-graph heterogeneity, meaning variability in how the splice junctions connect exons across samples, that they characterize as not readily identifiable using automated assembly or single-sample visualization. In other words, at even these well-trodden genomic addresses, the cohort-level view surfaced structural detail that mainstream tools had been leaving on the table.

Performance matters as much as discovery in a tool meant for daily research use, and the team benchmarked the platform across representative genes spanning a wide range of read-depth regimes, including extreme local coverage of the kind encountered at hyper-expressed loci such as MALAT1. The benchmarks show predictable latency and memory scaling, meaning that response times and memory consumption grow in a controlled, anticipatable way as the amount of sequencing data at a locus increases. That predictability is more than an engineering nicety. Researchers exploring weak transcriptional signals need to know that panning across a gene with enormous depth of coverage will not crash the session or freeze the interface, and the benchmarking suggests the Rust-and-caching design delivers exactly that stability even under the punishing local coverage that some of the most biologically interesting regions produce.

The broader significance of the work lies in a quiet tension running through modern genomics. Automated pipelines are indispensable, and no one proposes abandoning them; they process thousands of samples with consistency and scale no human can match. But they encode assumptions, and those assumptions are calibrated to the signals that dominate most datasets: well-expressed, cleanly spliced, protein-coding transcripts. Non-coding RNAs, with their low abundance, tissue specificity, and splicing variability, sit precisely at the margins where those assumptions break. By combining cohort-level aggregation with expert-driven, manual reconstruction, lncRNA Seeker Hub represents a hybrid model of discovery in which the machine does the heavy lifting of data handling and the human contributes pattern recognition and biological judgment. The authors position the platform, accordingly, as a practical framework for cohort-level RNA-seq exploration and manual transcript validation rather than as a replacement for assembly pipelines.

For the lncRNA field specifically, the implications could be considerable. Thousands of long non-coding RNAs have been catalogued, but annotations remain incomplete and uneven, and many candidate transcripts in public databases rest on thin or inconsistent evidence. Tools that can marshal the collective weight of large sequencing cohorts, from population genomics projects to cancer specimen collections, offer a route to confirming which of these faint transcriptional whispers are real, reproducible biology and which are noise. If weak lncRNAs regulating cancer pathways, immune responses, or developmental programs have been hiding below the detection threshold of automated assembly, platforms like this one give researchers a credible way to bring them into view, and potentially into the clinic, since molecules like PCA3 already demonstrate that non-coding transcripts can serve as disease biomarkers.

The software arrives as open-access research, citable under a permanent digital object identifier in BMC Bioinformatics, and the published version represents peer-reviewed, accepted work. Whether lncRNA Seeker Hub becomes a standard fixture in transcriptomics laboratories will depend on adoption and on how the community balances automated throughput with manual curation. But the message of the paper is clear and likely to resonate well beyond bioinformatics: some of the genome’s most important signals are individually too faint for machines to trust, yet collectively unmistakable when the right tools make them visible. Sometimes the next discovery is not hidden in the data so much as hidden in the aggregation of the data, waiting for a browser built to show it.

Subject of Research: Cohort-level RNA-seq visualization software for discovering weakly expressed long non-coding RNAs

Article Title: lncRNA Seeker Hub: cohort-level RNA-seq visualization and manual transcript reconstruction for weak lncRNA discovery

Article References: Kim, P.-S., Heese, K., & Kutzner, A. (2026). lncRNA Seeker Hub: cohort-level RNA-seq visualization and manual transcript reconstruction for weak lncRNA discovery. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06671-1

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06671-1

Keywords: lncRNA, RNA-seq, transcript discovery, bioinformatics software, genome visualization, splice junctions, MALAT1, PCA3, cohort analysis, Rust programming, BAM aggregation, non-coding RNA